CD79b–CD3 Multispecific Antibodies for T-Cell Tumor Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for CD79b-related diseases, such as B-cell lymphomas, lack effective methods to target and activate cytotoxic T cells for targeted cancer cell killing, and bispecific antibodies that recognize both CD79b and CD3 have limited therapeutic potential.
Innovation Solution
Development of multispecific antibodies that can simultaneously bind to CD79b and CD3, facilitating the connection of cytotoxic T cells with cancer cells to induce cytotoxic T cell-mediated cancer cell killing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monospecific antibodies targeting CD79b are used, then B-cell tumor targeting is achieved, but T cell activation and cytotoxic killing are not sufficient
Solution Approach 1:
The patent combines two separate antibody specificities (anti-CD79b and anti-CD3) into a single multispecific antibody molecule. This merging allows the antibody to simultaneously perform B-cell tumor targeting through CD79b binding and T-cell activation through CD3 binding, thereby resolving the contradiction between reliable tumor killing and versatile immune mechanism coverage.
Solution Approach 2:
The multispecific antibody is designed to perform multiple functions within a single molecule: it can bind to CD79b on B-cell tumors for targeted recognition, bind to CD3 on T cells for activation, and facilitate crosslinking to enable cytotoxic killing. This multi-functionality addresses the limitation of monospecific antibodies that can only perform one function at a time.
2Reliability
If bispecific antibodies targeting CD79b and CD3 are developed, then T cell-mediated cytotoxic killing is enhanced, but antibody structural complexity increases
Solution Approach 1:
The patent employs segmented antibody structures such as scFv (single-chain variable fragment) and Fab fragments that can be independently assembled. This segmentation allows for modular construction of the multispecific antibody, making the complex structure more manageable and easier to produce while maintaining the dual specificity for CD79b and CD3.
Solution Approach 2:
The patent introduces linker peptides as intermediary elements that connect different antibody fragments (e.g., connecting scFv-CD79b to scFv-CD3). These linkers serve as mediators that facilitate the assembly of complex multispecific structures while maintaining flexibility and proper spatial orientation of the binding domains.
3Reliability
If multisspecific antibodies are produced through recombinant methods, then therapeutic efficacy is improved, but manufacturing process complexity increases
Solution Approach 1:
The patent designs the antibody sequences with predetermined modular structures (scFv, Fab, Fc regions) that can be independently expressed and purified before final assembly. This preliminary preparation of standardized building blocks simplifies the overall manufacturing process by enabling modular assembly through well-established recombinant protein techniques rather than requiring de novo production of the complete multispecific molecule.
Data Source
AI summary
The disclosure relates to a multispecific (e.g., bispecific) antibody, which includes a first antigen-binding domain that specifically binds to a first antigen and a second antigen-binding domain that specifically binds to a second antigen. The first antigen is CD79b and the second antigen is not CD79b. The disclosure also relates to nucleic acid molecules, vectors and host cells encoding the bispecific antibodies, derivatives of the bispecific antibodies, and their use for disease treatment.